Evidence map›Paper›PMID 35368557›Full record

ArticleKidney3602022

Urine Neutrophil Gelatinase-Associated Lipocalin and Kidney Injury Molecule-1 to Detect Pediatric Cisplatin-Associated Acute Kidney Injury.

Kelly R McMahon, Hayton Chui, Shahrad Rod Rassekh, Kirk R Schultz, Tom D Blydt-Hansen, Cherry Mammen, Maury Pinsk, Geoffrey D E Cuvelier, Bruce C Carleton, Ross T Tsuyuki and 9 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney360, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 11 institutions in 2 countries.

Kelly R McMahonDivision of Nephrology, Department of Pediatrics, Research Institute of the McGill University Health Centre, McGill University Health Centre, Montreal Children's Hospital, Montreal, Quebec, Canada.ORCID 0000-0001-7362-6088
Hayton ChuiPeter Gilgan Centre for Research and Learning, Toronto, Ontario, Canada.
Shahrad Rod RassekhDivision of Hematology/Oncology/Bone Marrow Transplantation, Department of Pediatrics, University of British Columbia, British Columbia Children's Hospital, Vancouver, British Columbia, Canada.ORCID 0000-0001-8005-2641
Kirk R SchultzDivision of Hematology/Oncology/Bone Marrow Transplantation, Department of Pediatrics, University of British Columbia, British Columbia Children's Hospital, Vancouver, British Columbia, Canada.
Tom D Blydt-HansenDivision of Pediatric Nephrology, Department of Pediatrics, University of British Columbia, British Columbia Children's Hospital, Vancouver, British Columbia, Canada.ORCID 0000-0002-8864-0197
Cherry MammenDivision of Pediatric Nephrology, Department of Pediatrics, University of British Columbia, British Columbia Children's Hospital, Vancouver, British Columbia, Canada.
Maury PinskDepartment of Pediatrics and Child Health, Section of Pediatric Nephrology, University of Manitoba, Winnipeg, Manitoba, Canada.ORCID 0000-0001-7668-665X
Geoffrey D E CuvelierDivision of Pediatric Oncology-Hematology-BMT, Department of Pediatrics and Child Health, University of Manitoba, CancerCare Manitoba, Winnipeg, Manitoba, Canada.ORCID 0000-0003-4493-8757
Bruce C CarletonDivision of Translational Therapeutics, Department of Pediatrics, University of British Columbia and BC Children's Hospital and Research Institute, Vancouver, British Columbia, Canada.ORCID 0000-0002-4485-4054
Ross T TsuyukiEPICORE Centre, Department of Pharmacology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.ORCID 0000-0002-3724-598X
Colin J D RossFaculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Prasad DevarajanDivision of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio.ORCID 0000-0002-7847-8552
Louis HuynhFaculty of Health Sciences, Queen's University, Kingston, Ontario, Canada.
Mariya YordanovaFaculty of Medicine and Health Sciences, Sherbrooke University, Sherbrooke, Quebec, Canada.
Frédérik Crépeau-HubertDivision of Nephrology, Department of Pediatrics, Research Institute of the McGill University Health Centre, McGill University Health Centre, Montreal Children's Hospital, Montreal, Quebec, Canada.
Stella WangPeter Gilgan Centre for Research and Learning, Toronto, Ontario, Canada.ORCID 0000-0003-1338-6953
Vedran CockovskiPeter Gilgan Centre for Research and Learning, Toronto, Ontario, Canada.
Ana PalijanDivision of Nephrology, Department of Pediatrics, Research Institute of the McGill University Health Centre, McGill University Health Centre, Montreal Children's Hospital, Montreal, Quebec, Canada.
Michael ZappitelliDepartment of Pediatrics, Division of Nephrology, Toronto Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0002-9977-0536
University of British Columbia · CAMontreal Children's Hospital · CACentre for Global Health Research · CACancerCare Manitoba · CACincinnati Children's Hospital Medical Center · USMcMaster University Medical Centre · CAQueen's University · CAUniversité de Sherbrooke · CAUniversity of Alberta · CAUniversity of Manitoba · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Few studies have described associations between the AKI biomarkers urinary neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) with AKI in cisplatin-treated children. We aimed to describe excretion patterns of urine NGAL and KIM-1 and associations with AKI in children receiving cisplatin. Methods: Participants ( Results: Of 159 children, 156 (median [interquartile range (IQR)] age: 5.8 [2.4-12.0] years; 78 [50%] female) had biomarker data available at early cisplatin infusions and 127 had data at late infusions. Forty six of the 156 (29%) and 22 of the 127 (17%) children developed AKI within 10 days of cisplatin administration after early and late infusions, respectively. Urine NGAL and KIM-1 concentrations were significantly higher in patients with versus without AKI (near hospital discharge of late cisplatin infusion, median [IQR] NGAL levels were 76.1 [10.0-232.7] versus 14.9 [5.4-29.7] ng/mg creatinine; KIM-1 levels were 4415 [2083-9077] versus 1049 [358-3326] pg/mg creatinine; Conclusions: Urine NGAL and KIM-1 were modest at discriminating for cisplatin-associated AKI. Further research is needed to determine clinical utility and applicability of these markers and associations with late kidney outcomes.

Indexed as

Acute Kidney InjuryCisplatinCanadaChildChild, PreschoolFemaleHumansKidneyLipocalin-2Prospective StudiesCisplatinLipocalin-2acute kidney injuryacute kidney injury and ICU nephrologychemotherapycisplatin nephrotoxicitycohort studiesdiagnostic testingkidney injury molecule-1neutrophil gelatinase-associated lipocalinpediatric hematology/oncologypediatric nephrologyurine biomarkers

Identifiers

PMID35368557
PMCPMC8967607
OpenAlexW3211264458

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.